azenosertib — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-01 in 2mo
ESTIMATED |
READOUT
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Se
Phase 2 · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
K-Group, Beta, Inc., a wholly owne | azenosertib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|